Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (400)	1/7/1999 10:35:00 PM
From: scaram(o)uche	Respond to of 1073

B.J.: Here it is. Shocked me at first, but..... actually, it sort of makes sense and I accept it at "moving on" face value. Wednesday December 23, 12:00 pm Eastern Time Company Press Release SOURCE: CuraGen Corporation CuraGen Corporation Announces Departure of Gregory T. Went, Ph.D. NEW HAVEN, Conn., Dec. 23 /PRNewswire/ -- CuraGen Corporation (Nasdaq: CRGN - news), an integrated genomics-based discovery company, today announced the departure of Gregory T. Went, Ph.D., Executive Vice President. Dr. Went intends to seek a new opportunity and will also resign from the Company's Board of Directors. Upon this announcement, Jonathan Rothberg, Ph.D., Chief Executive Officer of CuraGen stated, ''Although Greg has decided to leave CuraGen, I am pleased to announce that he will remain as a consultant, as CuraGen embarks upon the Company's commercialization stage.'' Dr. Rothberg continued, ''Over the past five years, CuraGen has grown into a dynamic, 300-person organization that is developing processes for simplifying and accelerating genomics-based drug discovery and development. Greg has played a major role in helping CuraGen reach this juncture. CuraGen has in place a very capable team to continue establishing more business partnerships, and functioning as a successful public company. Greg is a good friend, and I support his decision to seek a new challenge.'' Gregory Went, Ph.D., stated, ''One of the most gratifying activities for me has been to create, integrate, and apply new technologies that can transform our understanding of biology and to speed the development of new products. I have enjoyed participating in CuraGen's evolution from a fledging start-up -- into a company poised to fulfill its corporate mission of developing treatments for disease. Now that CuraGen has reached this phase in its development, I am ready to move on to a new opportunity.'' Moving forward, the Company plans to increase its pharmaceutical customer base, continue to seek broad patent protection, enhance its proprietary suite of technologies, intensify its internal product development programs, and significantly expand the breadth of its senior management team. Business development activities will continue to be executed by Peter A. Fuller, Ph.D., Vice President, Business Development, and his team, which will be further expanded in coming months. CuraGen has already achieved scientific and commercial successes, including the recent launch of its SeqCalling™ database and the Company's discovery of more than 60,000 human cSNPs (genetic variations underlying human disease and drug response). CuraGen has successfully entered the international pharmaceutical arena, reflected by the Company's collaboration with Glaxo Wellcome, under which CuraGen will assist Glaxo Wellcome in the selection of drug candidates with the highest potential for clinical success. (snip)